{"id":51689,"date":"2026-05-20T10:07:33","date_gmt":"2026-05-20T08:07:33","guid":{"rendered":"https:\/\/www.bricbordeaux.com\/event\/bric-prestige-seminar-lionel-larue\/"},"modified":"2026-06-05T17:49:08","modified_gmt":"2026-06-05T15:49:08","slug":"bric-prestige-seminar-lionel-larue","status":"publish","type":"tribe_events","link":"https:\/\/www.bricbordeaux.com\/en\/event\/bric-prestige-seminar-lionel-larue\/","title":{"rendered":"BRIC prestige seminar \u2013 Lionel LARUE"},"content":{"rendered":"

As part of the prestigious seminars organized by our BRIC unit, we are pleased to welcome Dr. Lionel Larue<\/a><\/strong>, Inserm Research Director Emeritus, and Dr. V\u00e9ronique Delmas<\/a> (CNRS Research Director) from the Chemistry and Modeling for Cancer Biology team (UMR9187 \/ U1196)<\/a> at the Institut Curie<\/a>.<\/p>\n

We will take advantage of their visit to organize meetings with the researchers and students in our unit (see internal email)<\/p>\n

Their research focused on the role of E-cadherin and \u03b2-catenin, as well as other cadherins (such as N- and R-cadherin), in embryonic development, using sophisticated genetically modified mouse models (knockout\/knock-in, etc.), contributing to the study of the role of these proteins and their alterations in pathophysiology.<\/p>\n

They have long been interested in the development of various tissues and cell types, including the mammary gland and melanocytes, and their team has made a name for itself particularly in the study of melanoma.<\/p>\n

 <\/p>\n

The seminar will be presented by Lionel Larue<\/strong> at 9:30 a.m. on Tuesday, June 16, 2026<\/strong>, in a hybrid format<\/p>\n

BBS conference room, 2 rue Dr Hoffmann Martinot. location map<\/a><\/p>\n

Zoom ID 871 6813 2700 <\/a><\/p>\n

The presentation will be in English.<\/p>\n

\u201cThe CDH1-ESR1-GRPR axis defines a sex-specific metastatic pathways in cancer \u201d<\/p>\n

Abstract:<\/p>\n

Sex differences in cancer remain underexplored, limiting precision medicine. We show that premenopausal women are more susceptible to certain cancers and identify ECAD as a key mediator of estrogen response. In melanoma, an ECAD\u2013\u03b2CAT\u2013ER\u03b1\u2013GRPR pathway drives female-specific tumor aggressiveness, while targeting GRPR or ER\u03b1 reduces metastasis. These findings highlight hormone-dependent mechanisms in non-classical cancers and support sex-specific therapeutic strategies, including GPCR targeting. <\/p>\n

\"\ud83e\udd1d\" If scientists from outside the BRIC unit would like to meet with Dr. Lionel Larue and Dr. V\u00e9ronique Delmas, please contact David Cappellen at david.cappellen@u-bordeaux.fr.<\/span><\/span><\/p>\n

 <\/p>\nLionel Larue CV<\/a>\nJoin the webinar on Zoom<\/a>\n

 <\/p>\n

Curie Institute report on the article published in Nature in June 2025: Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin<\/strong><\/span><\/a><\/p>\n